Novel Radiolabeled ADC Could Improve Outcomes in High-Risk AML

Older patients with active, relapsed, or refractory acute myeloid leukemia have a low survival rate, very poor risk assessments, and limited therapeutic options, with conventional care consisting primarily of salvage chemotherapy.

Read full article (External website)

1 reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply